Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tagitanlimab - Harbour BioMed/Sichuan Kelun-Biotech Biopharmaceutical

Next Previous
Drug Profile

Tagitanlimab - Harbour BioMed/Sichuan Kelun-Biotech Biopharmaceutical

Alternative Names: A-167; HBM-9167; KL-A167

Latest Information Update: 18 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sichuan Kelun-Biotech Biopharmaceutical
  • Developer Sichuan Kelun Pharmaceutical Research Institute
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nasopharyngeal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Nasopharyngeal cancer
  • Phase II Breast cancer; Hodgkin's disease; Non-small cell lung cancer

Most Recent Events

  • 15 Aug 2025 Henan Cancer Hospital plans a phase II trial for Non small cell lung cancer (Combination therapy, Neoadjuvant therapy, First-line therapy) in August 2025 (NCT07108816)
  • 07 Aug 2025 West China Hospital plans a phase II (NeoSaciA) trial for HER2 negative breast cancer (Combination therapy, Neoadjuvant therapy, Early stage disease, First line therapy) (IV, injection) in September 2025 (NCT07109284)
  • 30 May 2025 Efficacy and adverse events data from a phase II trial in Non-small Cell Lung Cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top